Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACH-0141625 with peginterferon alfa-2a and ribavirin in chronic hepatitis C genotype 1
2010-022092-65Phase 2Completed
- Sponsor
- Achillion Pharmaceuticals
- Start
- Nov 2010
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing ACH-0141625 + peginterferon alfa-2a + ribavirin with Placebo + peginterferon alfa-2a + ribavirin (2 arms). Primary endpoint: RVR4. Started Nov 2010; status: completed.
02
Drugs
sovaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-022092-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022092-65.